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Abstract: This article explores the relationship between the renal expression of cystathionine gamma lyase (CSE) and endothelial nitric
oxide synthase (eNOS) and the responsiveness of α1A adrenergic receptors in the renal vasculature following left ventricular hypertrophy
(LVH) in rats. LVH was established by administering isoprenaline (5 mg/kg, 5 injections subcutaneously, 72 h apart) with 62 mg/L
caffeine in drinking water for 2 weeks. Renal vasoconstrictor responses were measured using local administration of adrenergic agonists
noradrenaline (NA), phenylephrine (PE), and methoxamine (ME) and the selective α1A adrenergic antagonist 5-methylurapidil (5MeU). Mean arterial blood pressure was higher (144 ± 9 vs. 116 ± 4 mmHg) and renal cortical blood perfusion was lower in the LVH
group (102 ± 5 vs. 157 ± 19 bpu) compared to the control group (P < 0.05). There was a 68% downregulation of mRNA for renal CSE
and 79% for eNOS in the LVH group compared to the control group (taken as 100%) (P < 0.05). The high dose of 5-MeU attenuated the
vasoconstrictor responses to NA by 33%, PE by 44%, and ME by 43% in the LVH group compared to the same dose in the control group.
The reductions in basal renal cortical perfusion and α1A adrenergic receptor vasoconstrictor responses in LVH were associated with the
downregulation of the CSE/H2S and eNOS/NO pathways.
Key words: Adrenergic receptors, isoprenaline, caffeine, left ventricular hypertrophy

1. Introduction
The development of left ventricular hypertrophy (LVH)
occurs because of many factors, including increased heart
work and the sympathetic nervous system. Activation
of the sympathetic nervous system is associated with an
increase in left ventricle mass (Burns et al., 2007) and may
occur because of increased workload on the heart due to
a raised total peripheral resistance. It has been observed
that the addition of adrenergic agonists to perfusing
media stimulates the in vitro growth of myocytes and
the replication of vascular smooth muscle cells, whereas
both phenomena can be blocked by adding adrenergic
antagonists (Sen et al., 1974). The isoprenaline and
caffeine model (I/C model) of LVH is known to result
in elevated plasma levels of noradrenaline (NA) and
angiotensin II (Daly et al., 1971; Leenen et al., 2001).
Increased sympathetic nerve activity is known to have an
impact on vascular function and impairs α1 adrenoceptormediated renal vasoconstriction (Sun and Hanig, 1983).
* Correspondence: munavvar@usm.my

The functional contribution of α1 adrenergic receptors in
different disease states with sympathetic hyperactivity has
been studied (Sattar and Johns, 1994a, 1994b). However,
little information is available as to the impact of LVH on
the responsiveness of the renal vasculature to exogenously
administered adrenergic agonists.
Hydrogen sulfide (H2S), carbon monoxide (CO), and
nitric oxide (NO) are endogenously produced lipid-soluble
gaseous messenger molecules (Nicholson and Calvert,
2010). H2S is produced from cysteine by two enzymes,
cystathionine gamma lyase (CSE) and cystathionine beta
synthase (CBS) (Hosoki et al., 1997; Chen et al., 2004).
CSE is found in many tissues, including the kidney
(Hosoki et al., 1997). CSE activity is the predominant
source of H2S generation in the cardiovascular system
(Wang, 2002). NO is produced by endothelial nitric oxide
synthase (eNOS) (Brunner et al., 2001) and is known as
a potent vasodilator (Ignarro et al., 1987). The CSE/H2S
(Zhao et al., 2001) and eNOS/NO (Moncada et al., 1991;
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Bredt and Snyder, 1992) pathways are both vasodilators
and share the guanylyl cyclase/guanosine monophosphate
pathway, which is operated by a G-protein coupled second
messenger pathway system. The CSE/H2S and eNOS/
NO mediate the common guanylyl cyclase/guanosine
monophosphate pathway for many of their actions and
are supposed to stimulate each other’s production. The
interlinked production of H2S and NO has been a topic of
interest (Hosoki et al., 1997; Wang, 2002). The adrenergic
receptors also operate via the G-protein coupled pathway
(Guimarães and Moura, 2001). Hence, downregulation
of the vasodilation CSE/H2S and eNOS/NO pathways
may also downregulate adrenergic receptors. The CSE/
H2S and eNOS/NO pathways, being vasodilators, would
be expected to modulate the vasoconstriction mediated
by noradrenaline released from sympathetic nerves or
angiotensin II, as associated with the I/C model of LVH.
Pharmacological and molecular studies have
documented three subtypes of α1 adrenergic receptors:
α1A, α1B, and α1D (Hieble et al., 1995; Han et al., 2003),
all from a G-protein coupled family (Guimarães and
Moura, 2001). In the renal vasculature, α1A adrenoceptors
are reported to be the major subtype contributing to
the constriction of the resistance vessels, intralobular
arteries, and afferent and efferent arterioles (Sattar and
Johns, 1994). The functional importance of this subtype
has been evaluated in many pathophysiological states
such as fructose-induced hypertension (Abdulla et al.,
2011), stroke-prone hypertensive rats, the two-kidney
one-clip model, and deoxycorticosterone acetate-salt
hypertensive rats. In the aforementioned studies, renal
vasoconstriction is mediated either by α1A (Sattar and
Johns, 1994a, 1994b; Villalobos-Molina and Ibarra, 1996),
or by both α1A and α1D adrenoceptor subtypes (VillalobosMolina et al., 1997; Salomonsson et al., 2000). Although
reduced responsiveness of α1D adrenoceptors in LVH
was reported in our previous study (Ahmad et al., 2014),
data are still lacking on the situation within the renal
vasculature in LVH. However, there have been reports
of α1A adrenoceptors being involved in heart failure, an
advanced stage of LVH, and diabetic Sprague–Dawley rats
(Abbas et al., 2007).
We hypothesized that increased sympathetic activity
due to induction of LVH in the I/C model and the
consequent vasoconstriction due to raised plasma levels
of noradrenaline and angiotensin may downregulate the
vasodilatory CSE/H2S and eNOS/NO pathways in the
kidney and depress the α1A adrenergic responsiveness to
exogenously applied adrenergic agonists.
2. Materials and methods
Male Wistar Kyoto (WKY) rats (240 ± 10 g) were obtained
from the animal house of Universiti Sains Malaysia, kept
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for 5 days of acclimatization in the animal transit room,
and given free access to tap water and standard chow
(Gold Coin Sdn. Bhd., Penang, Malaysia). These animals
were randomly divided into four groups for 2 sets of
experiments. One set consisted of control WKY and LVH
WKY rats for vasoconstrictor study (n = 6), and the second
set consisted of the same groups for molecular expression
of CSE and eNOS mRNAs (n = 9) in the cortex part of
the kidneys. LVH was induced by a modification of an
earlier model using 5 injections of isoprenaline (5 mg/kg
subcutaneously) on days 1, 4, 7, 10, and 13, and caffeine
was given in the drinking water (62 mg/L), as reported
by Ahmad et al. (2014). This approach is similar to a
previously reported model (Flanagan et al., 2008), where
only 4 injections of the same dose of isoprenaline were
given. The control group was given 5 injections of saline
within the same time intervals as the LVH group. This
model and experimental procedure was approved by the
Animal Research and Service Centre of Universiti Sains
Malaysia with approval no./ 20 1 2 / (76) (364).
2.1. Chemicals
2.1.1. Agonists
Noradrenaline (Sanofi Winthrop, Surrey, UK) is a
nonselective α adrenergic agonist that acts on α1 and α2
adrenergic receptors. Phenylephrine (Knoll, Nottingham,
UK) has the ability to act nonselectively on α1A, α1B, and α1D
(Armenia et al., 2004). Methoxamine (Wellcome, London,
UK) is relatively selective for α1A adrenoceptors (ArévaloLeón et al., 2003; Armenia et al., 2004) and can activate
α1D, but cannot differentiate between α1A and α1D (ArévaloLeón et al., 2003).
2.1.2. Antagonists
The antagonist 5-methylurapidil (5-MeU; Research
Biochemicals International, Natick, MA, USA) is a
selective antagonist for the α1A adrenoceptor subtype
(Gross et al., 1988).
2.2. Quantification of CSE and eNOS mRNAs using the
StepOnePlus RT-PCR system
After cervical dislocation, the kidney tissue was
immediately preserved in RNAlater Solution (Ambion,
Life Technologies, Pleasanton, CA, USA). Extraction
was performed in a contamination-free area cleaned
with RNaseZap (Ambion, Life Technologies). Total
RNA was extracted from kidney tissue using TRIzol
reagent (Ambion, Life Technologies) according to the
manufacturer’s guidelines. After the various sequential
steps of homogenization, washing, and elution, total
RNA was extracted, optimized, and quantified for purity
and yield respectively using a microplate reader (Bio-Tek
Instruments Inc., Winooski, VT, USA). Total RNA was
converted to cDNA using a High Capacity RNA-to-cDNA
kit (Applied Biosystems, Waltham, MA, USA) according
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to the manufacturer’s instructions. In this step, a 20-µL
volume was used for the conversion of RNA to cDNA. Of
the 20 µL, 11 µL comprised kit components (2X buffer, 10
µL; 20X enzymes, 1 µL), and the remaining 9 µL consisted
of total RNA (depending upon the yield). RNAse-free
water was used. The conversion of cDNA was performed
using the default settings of the StepOnePlus RT-PCR
system (Applied Biosystems) for this procedure.
TaqMan primers and probes for the CSE gene (GenBank
Accession Nos. NM_017074.1 and Rn00567128_m1) were
derived from TaqMan-Gene Expression assays (Applied
Biosystems) (Hassan et al., 2012). TaqMan primers and
probes for the eNOS gene (GenBank Accession Nos.
NM_021838.2 and Rn02132634_s1) were derived from
TaqMan-Gene Expression assays (Applied Biosystems)
(Lee et al., 2013; Xu et al., 2013). Similarly, TaqMan primers
and probes for the β-actin gene (GenBank Accession Nos.
NM_031144.2 and Rn00667869_m1) were derived from
TaqMan-Gene Expression assays (Applied Biosystems)
(Cannino et al., 2009; Sántha et al., 2012).
The following primers for CSE, eNOS, and the internal
control β-actin were used along with TaqMan chemistry
(assay IDs: Rn00567128_ml, Rn002132634_s1, and
Rn00667869_ml, respectively) for gene expression assays.
TaqMan-Gene Expression assays were obtained and the
procedure was followed according to the instructions of
the manufacturer (Applied Biosystems). The amplification
reaction consisted of a total of 20 µL of reaction mixture.
One RT-PCR reaction consisted of 10 µL of TaqMan Fast
Advanced Master Mix (2X) (Applied Biosystems); 1 µL of
TaqMan Gene Expression assays (20X) of the respective
genes CSE, eNOS, and beta-actin (Applied Biosystem); 8
µL of RNase-free water (Invitrogen, Carlsbad, CA, USA);
and 1 µL of unknown sample cDNA. As a negative control
of all the reactions, distilled water was added instead of
cDNA. Temperature settings for RT-PCR were followed
as default settings by the manufacturer (StepOnePlus RTPCR, Applied Biosystems). Special MicroAmp Fast 96well reaction plates (0.1 mL) (Applied Biosystems, Life
Technologies) were used in the RT-PCR for amplification.
Quantitative RT-PCR reactions were carried out on 3
experimental animals and each rat was further analyzed
in triplicate using the cortex of the kidney. Amplification
of the housekeeping enzyme (internal control) β-actin
allowed sample loading and normalization to be
determined. For the relative quantification of target genes
CSE, eNOS, and internal control β-actin, the comparative
CT (threshold cycle) method with the arithmetic formula
(2–ΔΔCT) was used (Livak and Schmittgen, 2001).
2.2.1. Western blot analysis for CSE protein
CSE protein was determined with the method adopted
previously (Zhu et al., 2010). Tissues were homogenized
in the presence of lysis buffer consisting of 60 mmol/L

Tris-HCl, 2% sodium dodecyl sulfate (SDS), 10% sucrose,
2 mmol/L phenylmethylsulfonyl ﬂuoride (Merck,
Darmstadt, Germany), 1 mmol/L sodium orthovanadate,
and 10 µg/mL aprotinin (Bayer, Leverkusen, Germany).
The cell lysates were quickly sonicated and centrifuged
at 12,000 × g for 5 min at 4 °C. The supernatant was
collected and the protein concentration was assayed using
a modiﬁed Bradford assay. The samples were diluted in
sample buffer (250 mmol/L Tris HCl (pH 6.8)) containing
4% SDS, 10% glycerol, 2% β-mercaptoethanol, and 0.002%
bromophenol blue and were boiled for a further 5 min.
Aliquots of proteins were separated by SDS-PAGE (10%)
and subsequently transferred to nitrocellulose membranes
by electroblotting. The membrane was blocked in 5%
skimmed milk powder in 0.1% Tris-buffered saline/Tween
20 (TBST) at room temperature for 2 h and then incubated
with antibody raised against CSE at a dilution of 1:2000
overnight at 4 °C. After three washes with TBST, the
membrane was incubated with a secondary horseradish
peroxidase-conjugated antibody for 1 h at room
temperature. Immunoreactive proteins were visualized
using the enhanced chemiluminescence western blotting
detection system. The light-emitting bands were detected
with X-ray ﬁlm. The resulting band intensities were
quantiﬁed using an image-scanning densitometer (Furi
Technology, Shanghai, China).
2.2.2. Nitric oxide synthase (NOS) protein analysis
Frozen hearts were homogenized in a buffer of 50
mmol/L Tris-HCL (pH 7.4), 1 mmol/L EGTA, 1
mmol/L dithiothreitol, 1 mmol/L pepstatin A, 2 mmol/L
leupeptin, and 1 mmol/L methanesulfonyl fluoride. All
the homogenates were centrifuged at 10,000 × g at 4 °C
for 60 min. Supernatant was taken as cytosolic fraction.
All the pellets were solubilized by buffer containing
10% glycerol and 20 mmol/L 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate
and
were
ultracentrifuged to extract the particular fraction.
About 150 g of protein samples were separated from
a particular fraction on 7.5% SDS-polyacrylamide gel,
which was transferred to polyvinylidene difluoride
membrane. About 5% nonfat dry milk was used to block
the blots and they were incubated with rabbit polyclonal
antibovine eNOS antibody (Ohashi et al., 1998; Ozaki et
al., 2002). Immunoreactive bands were visualized with
horseradish peroxidase-conjugated antirabbit IgG using
an ECL detection kit.
NOS enzyme activity was determined by the
conversion of [3H]-L-arginine to [3H]-L-citrulline with
saturating concentrations of substrate and cofactors (Ozaki
et al., 2002). Enzyme activity was expressed as citrulline
production in femtomoles per milligram of protein per
minute.
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2.3. In vivo acute experiments for renal vasoconstrictor
responses
An in vivo acute renal vasoconstrictor response
experiment was conducted using previously published
protocols (Abdulla et al., 2011). After overnight
fasting, animals were anesthetized with 60 mg/kg i.p
pentobarbitone (Nembutal, CEVA, Libourne, France).
The electrocardiographic electrodes were attached and
a tracheotomy was performed (PE240, Portex) using a
midline incision. The right carotid artery was cannulated
(PE50, Portex) and attached to a fluid-filled pressure
transducer (P23 ID Gould; Statham Instruments,
Nottingham, UK), whose output was connected to a data
acquisition PowerLab (ADInstruments, Sydney, Australia)
for continuous monitoring of blood pressure and heart
rate. The left jugular vein was cannulated (PE50, Portex)
for infusion of saline and maintenance doses of anesthetic.
The aorta and left kidney were exposed using a midline
abdominal incision. A laser Doppler flow probe (OxyFlow
Probe; Oxford Optronix Ltd., Oxford, UK) was placed on
the surface of the kidney to measure renal cortical blood
perfusion (RCBP) throughout the experiment (Roman et
al., 2001) and was connected to a laser Doppler flow meter
(ADInstruments). The left iliac artery was cannulated
(PE50, Portex) and the cannula was inserted into the
aorta until it reached a point adjacent to the entrance
of the renal artery. This cannula allowed the infusion of
saline noradrenaline (NA), phenylephrine (PE), and
methoxamine (ME) locally into the kidney. The saline
was infused at 3 mL/h and the cannula was attached to
a fluid-filled pressure transducer (P23 ID Gould; Statham
Instruments). The output of the pressure transducer
was attached to the PowerLab data acquisition system
(PowerLab, ADInstruments). The bladder was cannulated
for free urination. At the end of the surgery, the animals
were allowed to stabilize for 1 h to ensure stable readings
of systolic blood pressure (SBP), mean arterial pressure
(MAP), heart rate (HR), and RCBP.
2.3.1. Renal vasoconstrictor responses
The three adrenergic agonists NA, PE, and ME were
administered close renal arterially in ascending and
descending dose order. The responses of these agonists
in ascending and descending dose order were averaged to
get a mean % drop in RCBP. NA was used at 25, 50, 100,
and 200 ng; PE was used at 0.25, 0.5, 1, and 2 µg; and ME
was administered at 1, 2, 3, and 4 µg. These doses were
freshly prepared in saline solution every day and stored
at 4 °C (Hieble et al., 1995). Each experiment consisted of
three phases: a saline phase, and the low- and high-dose
antagonist phases (5-MeU). In the saline phase, saline
was administered intrarenally at a dose of 6 mL kg–1 h–1.
During this phase, all three agonists were administered in
their ascending order and then descending order. Between
each dose, agonists were washed out for 12 min for
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complete removal of the previous dose of agonist (Abdulla
et al., 2011). In the low-dose phase of antagonist, 5-MeU
was administered intrarenally as a bolus dose of 5 µg/kg
and then as a maintenance infusion of 1/4 of the bolus
dose (1.25 µg kg–1 h–1). In the low-dose phase, the doses
of each agonist were administered in the same pattern
as in the saline phase. In the high-dose phase, 5-MeU
was administered intrarenally as a bolus dose of 10 µg/
kg intrarenally, followed by a maintenance dose of 1/4 of
the bolus dose (2.5 µg kg–1 h–1). The doses of the agonists
followed the same pattern as in the saline and low-dose
phases. At the end of the acute vasoconstrictor study, the
animals were euthanized with pentobarbital.
2.3.2. Measurement of heart, LV, and kidney indices
After the completion of the acute experiment, the heart and
contralateral kidney were carefully extracted and dried on
blotting paper to prevent the interference of blood in the
weight measurement. The heart and kidneys were weighed
carefully, and then the LV was isolated from the whole
heart and carefully weighed. These values were used to
generate the heart, kidney, and LV indexes as follows:
Heart index = heart weight / body weight × 100
Left ventricle index = left ventricle weight / body weight × 100
Kidney index = kidney weight / body weight × 100

2.4. Measurement of H2S and NO concentrations in
plasma
A blood sample was taken from the tail artery on day
14 and was centrifuged at 5000 × g for 10 min (Ahmad
et al., 2014). The plasma was separated and used for the
estimation of H2S and NO. The plasma concentration of
nitric oxide was measured using kits, according to the
manufacturer’s instructions (NJJC Bio Inc., Nanjing,
China). The plasma concentration of H2S was measured as
reported previously (Yan et al., 2004; Ahmad et al., 2012).
2.5. Statistical analysis
In this study, the statistical analysis for vasoconstriction
was undertaken using two-way analysis of variance
(ANOVA), followed by a Bonferroni post hoc test and an
independent Student t-test for physical parameters of the
heart, systemic hemodynamic parameters, concentration
of H2S and NO, and expression of CSE and eNOS mRNAs.
Overall mean % drop in RCBP bar graphs was analyzed by
using one-way ANOVA followed by the Bonferroni post
hoc test using GraphPad Prism (GraphPad Software, San
Diego, CA, USA). All data were expressed as mean ± SEM
with significance at P < 0.05.
3. Results
3.1. Physical indices of heart and kidney
The kidney, heart, and LV indices were significantly
elevated (P < 0.05) in the LVH WKY group compared to
the control WKY rats (Table 1).
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Table 1. Physical parameters of kidney, heart, and LV in control WKY and LVH WKY
groups (n = 6).
Control WKY

LVH WKY

Heart index (%)

0.27 ± 0.01

0.39 ± 0.01*

Kidney index (%)

0.29 ± 0.00

0.34 ± 0.017*

LV index (%)

0.15 ± 0.01

0.24 ± 0.001*

WKY: Wistar Kyoto rats; LVH: left ventricular hypertrophy.
*P < 0.05 compared to the control.

3.2. Systemic hemodynamic data in control WKY and
LVH WKY groups
SBP and MAP were significantly elevated and HR was
reduced in LVH WKY compared to the control WKY (P
< 0.05). RCBP was lower in LVH WKY compared to the
control WKY group (P < 0.05), as shown in Table 2.
3.3. Measurement of H2S and NO concentrations in
plasma
The concentration of H2S in the plasma of LVH WKY
was significantly (P < 0.05) lower compared to the control
WKY (LVH WKY 16 ± 2 vs. control WKY 37 ± 3 µM),
as shown in Table 2. Similarly, the plasma concentration
of NO was reduced significantly (P < 0.05) in LVH WKY
compared to the control WKY (LVH WKY 21 ± 1 vs.
control WKY 25 ± 2 µmol/mL).
3.4. Expression of renal CSE mRNA, eNOS mRNA, and
respective proteins
Induction of LVH in WKY rats reduced the expression
of renal CSE mRNA to 0.32-fold relative to that of the
control WKY rats (P < 0.05). Similarly, the expression
of renal eNOS mRNA was also reduced in LVH WKY
rats by 0.21-fold compared to the control WKY rats (P <
0.05), as shown in Figures 1A and 1B. It can be seen by

the visualized band that both CSE and eNOS proteins are
reduced in the LVH group when compared to the control
group, as shown in Figures 1C and 1D.
3.5. Renal vasoconstrictor responses
The adrenergic agonists NA, PE, and ME produced dosedependent renal vasoconstrictions in both the control
WKY and LVH WKY groups, as shown in Figures 2A–2F.
The magnitude of the renal vasoconstrictor responses to
NA, PE, and ME in the saline phase in the LVH WKY rats
were significantly (P < 0.05) attenuated compared to the
control WKY group (NA, 27 ± 2% vs. 43 ± 6%; PE, 32 ±
7% vs. 44 ± 3%; ME, 29 ± 1% vs. 40 ± 6%) when data were
expressed as overall mean % drop in RCBP, as shown in
Figures 3A–3C.
With the low dose of the antagonist phase, the renal
vasoconstriction responses to NA and PE were not
attenuated in the LVH group when a comparison was
performed against the low-dose phase of the control WKY
group. However, there was a significant attenuation of the
responses of ME in the LVH WKY group as compared to
the low-dose phase of the control WKY (NA, 25 ± 2% vs.
29 ± 6%; PE, 28 ± 4% vs. 34 ± 3%; ME, 22 ± 2% vs. 32 ±
8%; Figures 3A–3C).

Table 2. Baseline values of SBP, MAP, HR, and RCBP were measured during the acute experiment on day 14 for
control WKY and LVH WKY groups (n = 6). *: Significance compared to LVH WKY (P < 0.05).
Parameters

Control WKY

LVH WKY

SBP (mmHg)

130 ± 7

160 ± 9*

MAP (mmHg)

116 ± 4

144 ± 9*

Heart rate (bpm)

314 ± 9

264 ± 18

RCBP (bpu)

157 ± 19

102 ± 5*

H2S (µM)

37 ± 3

16 ± 2*

NO (µmol/mL)

25 ± 1.30

21 ± 1*

SBP: Systolic blood pressure, MAP: mean arterial pressure, HR: heart rate, bpm: beats per min, RCBP: renal
cortical blood perfusion, bpu: blood perfusion unit, WKY: Wistar Kyoto rats, LVH: left ventricular hypertrophy,
H2S: hydrogen sulfide, NO: nitric oxide.
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Cystathionine γ lyase mRNA expression in kidney

C

A

Endothelial nitric oxide synthase RNA expression in kidney

D

B

Figure 1. Relative quantification of (A) CSE mRNA and (B) eNOS mRNA expression in the kidney of the control WKY and
LVH WKY. *: P < 0.05 compared to the control WKY group. The data are relative to the control WKY and normalized to internal
control β-actin. (C, D) Both CSE and eNOS proteins are reduced in the LVH group when compared to the control group.

In the high-dose phase of antagonist, there was no
attenuation of the renal vasoconstrictor response to NA
in the LVH WKY group when compared to the same
dose of the control WKY group (NA, 12 ± 2% vs. 18 ±
3%). However, at the same time, statistically significant
attenuation (P < 0.05) was observed in the LVH WKY
group when PE and ME were used in the high-dose phase
of 5-MeU (PE, 13 ± 1% vs. 23 ± 5%; ME, 12 ± 3% vs. 21 ±
1%; Figures 3A–3C).
4. Discussion
This investigation aimed to determine the mechanisms
contributing to renal vasoconstrictor responsiveness to
adrenergic agonists in a pathophysiological model of
LVH. The I/C treatment resulted in a marked increase
in left ventricular weight, demonstrating that LVH had
been induced; an increase in blood pressure, reflecting
an increase in total peripheral resistance; and a decrease
in RCBP, indicating elevated vascular resistance in the
kidney. There were two major novel observations. First,
there was a blunting of the renal vascular responsiveness
to the adrenergic agonists, which appeared to be primarily
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mediated via the α1 adrenoceptor subtype. Second, there
was a marked depression in the expression of the CSE and
eNOS genes in the kidney, suggesting that the generation
of vasodilators H2S and NO was reduced in this model of
LVH. The question that arises is whether the reduction
in H2S and NO and its association with reduced vascular
responsiveness is a direct one at the level of the signaling
cascades, or whether it is indirect as a consequence of the
increase in vascular tone.
After 2 weeks of treatment with caffeine and
isoprenaline, there was a significant increase in cardiac and
LV indices in the LVH WKY rats compared to the control
WKY rats, which is in agreement with previous reports
using this model (Flanagan et al., 2008). This increased
heart weight is probably due to an increase in workload
induced by isoprenaline acting on β1 adrenoceptors at
the sinoatrial node, which increases the heart rate and
cardiac output, thereby resulting in hypertrophy of the left
ventricle (Leenen et al., 2001). Nevertheless, the present
study and several previous studies using this LVH model
have shown a decrease in heart rate. The exact mechanism
is still unknown, but it may be due to the anesthetic used
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Figure 2. Line graph shows dose-dependent curves of the renal vasoconstrictor responses to the graded doses of
adrenergic agonists. (A, B) NA, (C, D) PE, (E, F) ME in the control WKY and LVH WKY groups in saline and low- and
high-dose phase 5-MeU. Values are mean ± SEM, n = 6 rats in each group. The significance is calculated as overall mean
responses of four doses of each agonist during each phase and compared with the saline phase.*: P < 0.05 vs. saline phase.

in these studies. SBP and MAP were significantly elevated
in the LVH group, which may be partly due to elevated
renin and angiotensin II levels, which have been reported
in this I/C model. Moreover, angiotensin II, acting either

systemically (Leenen et al., 2001) or locally in the kidney
(Crowley et al., 2006), will also contribute to blood pressure
elevation and cardiac hypertrophy. Interestingly, our data
are in contrast to previous studies using a similar model,
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Figure 3. Bar graph shows % drop in overall mean of change in renal cortical blood perfusion in response to NA, PE, and ME in
the presence and absence of 5-MeU antagonist in the control WKY and LVH WKY groups. Values are mean ± SEM, n = 6 rats in
each group. The significance is calculated as overall mean responses of four doses of each agonist during each phase and compared
with the saline phase. *: P < 0.05 vs. saline phase. #: P < 0.05 vs. low-dose phase of respective group. ψ: P < 0.05 vs. same phase of
the control WKY group.

which found that MAP did not change after 2 weeks of
treatment with isoprenaline and caffeine (Flanagan et al.,
2008). This may be due to the modification undertaken
in the model of the present study by administering 5
isoprenaline injections.
An important novel observation was that the induction
of LVH resulted in a decrease in the expression of the CSE
gene in the renal cortex of the kidney, which was probably
responsible for the decreased plasma levels of H2S.
Although only the kidney was examined in this study, it is
likely that a similar situation pertained to all other organs
of the body. It is recognized that H2S is a vasodilating
factor, and its decreased intrarenal production would lead
to an increased vascular tone and hence resistance within
the kidney. The way in which H2S exerts its action is
unclear, but there is evidence that it induces relaxation of
resistance vessels via activation of ATP-sensitive potassium
channels (Hosoki et al., 1997). Thus, the reduction in the
CSE/H2S axis in LVH would contribute to elevated blood
pressure and vascular resistance. A further novel finding
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was that, concomitantly, LVH caused a decrease in the
expression of eNOS in the renal cortex kidney, which was
reflected in the reduction in plasma NO concentrations.
NO induces vasodilation via activation of guanylyl cyclase
and therefore reduction in the eNOS/NO pathway would
also lead to an increase in tone in all resistance vessels,
including the kidney, as observed in the present study.
There is evidence that NO acts primarily on the larger
resistance vessels (Wilkinson et al., 2002). Together, the
reductions in the CSE/H2S and eNOS/NO pathways may
be the primary factors responsible for the increased blood
pressure and decreased renal cortical perfusion observed
in this LVH model. Moreover, the downregulation of
the CSE/H2S and eNOS/NO pathways indicates some
common pathway for the production of both gaseous
transmitters, which needs to be elucidated by upregulating
the one pathway and observing the production of H2S and
NO in future studies.
It was important to examine how the withdrawal of the
vasodilator factors, H2S and NO, would influence the ability
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of the adrenergic agonists to cause vasoconstriction in the
kidney. It was evident that there was a marked blunting
of the renal vasoconstrictor actions of all the adrenergic
agonists tested. The underlying reasons are unclear, but
there are two possibilities: direct and indirect. The first
possibility is that while the basal vascular tone within
the kidney is substantially elevated in the LVH model,
the ability of the agonists to increase the tone further
would be limited, reflected as reduced responsiveness.
A second possible mechanism is interference along the
signaling pathways. Binding of the α1 adrenoceptors to
their G-coupled proteins activates a cascade, whose end
point is an increase in intracellular calcium and opening of
calcium channels. However, if the smooth muscle cells are
already hyperpolarized as a consequence of the decrease in
H2S, then the ability of the alpha adrenergic compounds to
induce depolarization and contraction will be decreased.
In the present study, LVH was associated with a lower
RCBP compared to the control WKY, as shown in Table 2.
The downregulation of the vasodilator CSE/H2S pathway
may be one of the reasons for RCBP, as exogenous H2S
supply improves the RCBP in spontaneously hypertensive
rats (Ahmad et al., 2014). Another possibility is the
downregulation of the eNOS/NO pathway associated with
LVH induction. Decreased plasma NO concentration
would lead to an increased vascular tone, which would
be expressed in the kidney as decreased RCBP. A further
factor contributing to reduced RCBP would be the
increased plasma levels of NA and angiotensin II caused
by the activation of the sympathetic nervous system
(Collomp et al., 1991; Bell et al., 2001).
The attenuation of the vascular responses to the
adrenergic agonists NA, PE, and ME were significantly
blunted in the saline phase as well as with the low and
high doses of 5-MeU in the LVH WKY group compared
to control WKY. These attenuated responses to adrenergic
agonists may be due to elevated plasma levels of NA and
angiotensin II, as reported previously with this model
(Bell et al., 2001; Crowley et al., 2006). Our data are in
agreement with other pathophysiological studies, in
which elevated levels of circulating NA and angiotensin

II reduced the responsiveness of adrenergically mediated
vasoconstriction (Tran et al., 2009; Abdulla et al., 2011).
The reduced renal vasoconstrictor responses to NA, PE,
and ME during the saline phase of LVH WKY indicate that
α1 adrenergic receptor signaling cascades and/or vascular
responsiveness are attenuated, which may be due to the
downregulation of the CSE/H2S and eNOS/NO pathways.
The blockade of α1A adrenergic receptors by the low-dose
5-MeU in the control WKY group blunted the responses
to NA and PE but did not affect the responses of NA and
PE in LVH WKY, indicating that adrenergic receptors’
responsiveness to these nonselective α1A adrenoceptor
agonists was altered by the induction of LVH (Khan et
al., 2008). By contrast, the responses to ME, a relatively
selective agonist (Arévalo-León et al., 2003), were
unchanged in the WKY and LVH groups. However, the
partial or complete blockade of α1A adrenergic receptors
with 5-MeU attenuated the responses of the selective α1A
adrenergic receptor agonist. These findings suggest that
it is the α1A adrenoceptor subtype that is responsible for
the modulation of vasoconstrictor responses in LVH, and
the magnitude of these responses is attenuated with the
induction of LVH.
In conclusion, these findings suggest that the
downregulation of the CSE/H2S and eNOS/NO pathways
in the kidney and the blunted responses to the α1A
adrenergic agonists were consistent with an alteration in
the G-protein second messenger coupled pathway due
to the induction of LVH. Therefore, the upregulation of
both vasodilatory pathways is expected to ameliorate the
blunted responses of the α1A adrenergic receptor.
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